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Hypertension Rapid Communication
Hypotensive and Bradycardic Effects of Centrally
Administered Vasopressin in Stroke-Prone
Spontaneously Hypertensive Rats
YUTAKA IMAI, KEISHI ABE, SHUICHI SASAKJ, NAOYOSHI MINAMI, TOSHIMA NOBUNAGA,
HIROSHI SEKINO, AND KAORU YOSHINAGA
The cardiovascular effects of centrally administered arginine vasopressin were studied in stroke-
prone spontaneously hypertensive rats and Wistar-Kyoto rats. Arginine vasopressin was infused
intracerebroventricularly into conscious rats at a rate of 2 pg/kg/min (4.6 ^,1/hr) for 21 hours, and
blood pressure and heart rate were monitored. Arginine vasopressin caused transient hypertension
and tachycardia in Wistar-Kyoto rats, whereas it induced delayed hypotension and bradycardia in
stroke-prone spontaneously hypertensive rats. The effects on the latter lasted for 24 to 72 hours after
cessation of the infusion. Intravenous administration of arginine vasopressin at a rate of 2 pg/kg/min
did not cause any change in blood pressure and heart rate in these rats. These results suggest that
arginine vasopressin acts centrally to depress cardiovascular activities, at least in stroke-prone sponta-
neously hypertensive rats. (Hypertension 10: 346-349, 1987)
KEY WORDS * arginine vasopressin • intracerebroventricular administration
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Wistar-Kyoto rats
KCENT studies have shown that there are exten-sive extrahypothalamic axonal projections ofvasopressin neurons from the nuclei produc-
ing arginine vasopressin (AVP) precursor, the su-
praoptic nucleus and the para ventricular nucleus. The
major projections appear to be to brainstem nuclei,
including the nucleus tractus solitarii and dorsal vagal
nucleus, and the intermediolateral nucleus of the spinal
cord.12 Recently, the presence of AVP-containing
cells has also been reported in nonhypothalamic nuclei
in rats.3-4 All of these sites are known to be involved in
central cardiovascular regulation, and this suggests
that central vasopressin may act as a neuromodulator
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or a neurotransmitter (or both) involved in the central
cardiovascular regulatory mechanisms. Furthermore,
spontaneously hypertensive rats (SHR) and stroke-
prone SHR (SHRSP) of the Okamoto-Aoki strain have
been reported to have a lower concentration of AVP in
brainstem and hypothalamic nuclei when compared
with the normotensive parent strain, Wistar-Kyoto rats
(WKY).5"7
Despite this circumstantial evidence, the putative
role of central vasopressinergic mechanisms in cardio-
vascular regulation has not been fully elucidated. Re-
cently, AVP has been shown to have specific and di-
rect effects on the baroreceptor reflex function (see the
recent review by Johnston8). Liard et al.9 proposed that
the locus of these effects is in the central nervous
system. It has been observed that Brattleboro rats with
hereditary hypothalamic diabetes insipidus have sup-
pressed baroreceptor reflex function, and exogenous
AVP administered systemically or centrally restored
this function to the range in Long-Evans rats, the nor-
mal parent strain of Brattleboro rats.10 Reduced barore-
ceptor reflex function has also been demonstrated in
SHR." Inhibition of central baroreceptor reflex path-
ways is generally considered to raise blood pressure.12
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These links between blood pressure, baroreceptor re-
flex function, and AVP have prompted us to investi-
gate whether centrally administered AVP depresses
the blood pressure in SHR, especially in SHRSP.
Materials and Methods
We used male and female SHRSP (age, 19.5 ± 0.5
weeks; n = 7) and age-matched WKY (age, 20.2 ±
0.3 weeks; n = 7), obtained from the Institute for Ex-
perimental Animals, Tohoku University, Sendai, Ja-
pan. A cannula (PE-20 polyethylene tubing, 4.6 cm
long with a volume of approximately 4.6 fi\) was im-
planted into the left lateral ventricle with the rats under
pentobarbital anesthesia. Coordinates for implantation
with respect to the bregma were 1.0 mm posterior, 1.5
mm lateral, and 5 mm deep. The cannula was filled
with artificial cerebrospinal fluid (ACSF) and fixed in
place with stainless steel anchoring screws and ortho-
pedic bone cement. Seven days after the cerebroven-
tricular cannulation, the left femoral artery and vein
were cannulated using polyethylene tubing (tapered
PE-100 tubing for artery and PE-20 tubing for vein).
The catheters were passed subcutaneously and brought
out on the neck. The arterial catheter was connected to
a hydraulic, swivel-tethering system, and each rat was
placed in an individual plastic metabolic cage and
housed under conditions of constant temperature
(23 °C) and humidity (60%), with a 12-hour light/dark
cycle. To keep the arterial catheter patent, heparinized
saline solution (100 U/ml) was continuously infused at
a rate of 80 yul/hr.
The animals were fed a commercial diet and water
ad libitum. Blood pressure was recorded from the fem-
oral artery catheter using a P23Ib Statham pressure
transducer (Oxford, CA, USA) and strain-gauge am-
plifier (Model 1257; NEC-San-ei, Tokyo, Japan).
Heart rate was counted from phasic pressure wave by a
cardiotachometer (Model 1321; NEC-San-ei). The
analog signals of phasic pressure, mean arterial pres-
sure, and heart rate were fed to an analog/digital con-
verter (Mark 1; N.C.C., Tokyo, Japan). Digital sig-
nals of mean arterial pressure and heart rate from this
converter were fed to a microcomputer (Model HP-
9816; Hewlett-Packard, Fort Collins, CO, USA) every
4 seconds for 21 hours/day. The remaining 3 hours of
the day was devoted to calculation and printout. At the
end of each measurement period, the processed data
were printed out. Mean values and the standard devi-
ation averaged for each 10-minute, 1-hour, and 21-
hour period were calculated for each parameter and
plotted on time-trend charts and histograms.
To allow blood pressure and heart rate to stabilize,
the experiment was started at least 72 hours after the
operation. A time-control experiment was performed
on the fourth postoperative day and consisted of an
intracerebroventricular infusion of ACSF at a rate of
4.6 /il/hr. Twenty-four hours later, AVP (Protein Re-
search Foundation, Osaka, Japan) was infused i.c.v. at
a rate of 2 pg/kg/min (4.6 fil/hr) for 21 hours. AVP
was dissolved into ACSF to the desired concentration.
ACSF and AVP solutions were infused by means of a
Princeton infusion pump (Model 575; Natick, MA,
USA).
Following each infusion experiment, blood pressure
and heart rate were monitored for 2 to 3 days to follow
the recovery from the cardiovascular effects of the
AVP infusion. The reproducibility of the time course
of changes in blood pressure and heart rate in response
to the i.c.v. infusion of ACSF (4.6 /xl/hr) was exam-
ined in a separate experiment using eight WKY. The
i.c.v. infusion of ACSF was performed on the fourth
and sixth postoperative days. The effect of an intrave-
nous infusion of AVP at a rate of 2 pg/kg/min was also
examined in five SHRSP. The time course of cardio-
vascular changes was compared by two-way analysis
of variance for repeated measures. Comparisons be-
tween values obtained at specific time points and the
control value (zero hour in Figure 1) were made using
Duncan's multiple range test.
Results
The basal mean arterial pressures in WKY and
SHRSP were 118 ± 2 and 187 ± 12 mm Hg, respec-
tively, and basal heart rates were 370 ± 6 and 356 ±
15 beats/min, respectively. The i.c.v. infusions of
ACSF did not cause any cardiovascular changes. The
time course of changes in mean arterial pressure
(Fl314 = 0.24, /?>0.8) and heart rate (F, 3l4 = 0.59,
p>0.4) in response to i.c.v. ACSF infusion was suffi-
ciently reproducible. The i.c.v. infusions of AVP in-
duced a gradual decrease in mean arterial pressure in
six of seven SHRSP (time control vs i.c.v. AVP infu-
sion: F, JJ, = 96.9, /?<0.0001). In the remaining rat,
only an initial, transient increase in mean arterial pres-
sure was observed. The i.c.v. infusions of AVP also
induced a transient tachycardia followed by bradycar-
dia in all SHRSP. The bradycardic effect reached its
nadir 6 hours after the start of the infusion and was
followed by gradual recovery to the initial level
(time control vs i.c.v. AVP infusion: F, ^ = 32.0,
p< 0.0001; Figure 1). In contrast to the response seen
in SHRSP, i.c.v. infusions of AVP in WKY induced
elevations of blood pressure and tachycardia that re-
turned to the initial levels after 10 and 7 hours, respec-
tively (see Figure 1). No significant hypotension
(WKY vs SHRSP: F 1 2 3 9 = 194.2, p<0.0001) and
bradycardia (WKY vs SHRSP: F1 2 J 9 = 75.1, p<
0.0001) were observed in WKY.
The hypotensive effect of i.c.v. AVP infusion in
SHRSP persisted long after cessation of the infusion.
In one rat it took 72 hours to recover the initial blood
pressure level, while in the remaining rats the initial
level was recovered within 48 hours. Figure 2 shows
the time course of the changes in blood pressure during
and after an i.c.v. infusion of AVP in a single experi-
ment with SHRSP. The intravenous infusion of AVP at
a rate of 2 pg/kg/min in SHRSP had no effect on blood
pressure and heart rate (data not shown).
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FIGURE 1. Time course of changes in mean
arterial pressure (MAP) and heart rate (HR)
induced by i.c.v. infusions of artificial cere-
brospinal fluid and of arginine vasopressin
(AVP) at a rate of 2 pglkglminfor 20 hours in
WKY and SHRSP. Symbols and vertical bars
represent the means and SEM. Asterisk indi-
cates a significant difference (p<0.05) com-
pared with control values (Hour 0), by Dun-
can's multiple range test.
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Discussion
The present study clearly demonstrates that protract-
ed i.c.v. infusions of AVP in a low dose dramatically
decrease blood pressure and heart rate in SHRSP and
transiently increase these parameters in normal WKY.
Previous studies found that centrally administered
AVP caused hypertension and tachycardia in rats.13"16
In these earlier studies, however, huge amounts of
AVP were administered centrally for short periods "to
anesthetized or unanesthetized rats. In the present
study we infused a small amount of AVP for a long
period in a minimum infusion volume. Since rats
weighing 300 g may have 400 /i.1 of cerebrospinal
fluid17 and as the half-life of AVP in cerebrospinal
fluid is only a few minutes,18 the AVP concentration in
cerebrospinal fluid of rats would attain a steady state
concentration of 15 to 20 pg/ml according to the one-
compartment-open model when AVP is administered
i.c.v. at a rate of 2 pg/kg/min. This cerebrospinal fluid
concentration of AVP might still be unphysiologically
high, but it is certainly much closer to physiological
levels as compared with those expected in previous
short-term experiments.
Under such experimental conditions the previously
reported hypertensive effect of centrally administered
AVP was also observed in the present study in WKY.
This effect may be mediated by midbrain or brainstem
cardiovascular control mechanisms since microinjec-
tion of AVP to the nucleus tractus solitarii or locus
ceruleus produces tachycardia and hypertension.19-20
However, vasopressinergic neuronal projections are
not restricted to these regions; they are also found in
other central cardiovascular centers, such as the an-
teroventral third ventricle of the hypothalamus, the
dorsal vagal nucleus of the brainstem, and the interme-
diolateral nucleus of the spinal cord.12 These varied
sites suggest that central vasopressinergic mechanisms
have a dual function: to produce 1) cardiovascular
stimulation and 2) cardiovascular depression. Central
vasopressinergic neuronal mechanisms have been re-
ported to attenuate the centrally mediated pressor re-
sponses to electrical stimulation of the mesencephalic
reticular formation.21 Furthermore, central injection of
AVP causes bradycardia or hypotension, or both, in
cats22 and dogs.23 More recently, Imai et al.24 reported
that centrally administered AVP caused hypotension
1st day 2nd day 3rd day
i.cv.AVP2pg/kg min'
FIGURE 2. Time course of changes in mean arterial pressure (MAP) in a single experiment during and after an
i.c.v. arginine vasopressin (AVP) infusion at a rate of 2 pg/kg/min. Each vertical bar represents ± J SD of MAP
averaged over 10 minutes. The numbers at the top of each panel are rat identification numbers.
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and bradycardia in rats with hereditary hypothalamic
diabetes insipidus (Brattleboro) but not in normal
Long-Evans rats. These lines of evidence are consis-
tent with the hypothesis that decreased AVP levels in
several brain loci of SHR5"7 contribute to the induction
and maintenance of high blood pressure in this strain of
rat.
The precise reason why centrally administered AVP
causes hypotension and bradycardia only in SHRSP is
uncertain; however, the AVP-sensitive cardiovascular
depressor center in SHRSP may be more sensitive to
exogenous AVP than that in WKY. In normal WKY,
endogenous AVP may occupy or desensitize the region
where exogenous AVP induces cardiovascular depres-
sion in SHRSP; thus, additional AVP stimulation
would cause no further decrease in blood pressure and
heart rate. This hypothesis is supported by the evi-
dence that the AVP content of the brainstem and hypo-
thalamic nuclei in SHR and SHRSP is less than that in
the normotensive strain.5"7 One might even argue that
AVP in certain central regions may protect against the
development and maintenance of hypertension in rats.
The precise mechanism by which AVP modulates
central cardiovascular centers has not been elucidated,
although a number of studies have attempted to solve
this question. For example, vasopressin has been
shown to influence preganglionic sympathetic neurons
to change phosphatidylinositol turnover and calcium
kinetics in sympathetic ganglia and to modulate cate-
cholamine turnover and metabolism in medullary brain
nuclei (see the recent review by Johnston8). We ob-
served that the hypotensive effect of i.e.v. AVP infu-
sion in SHRSP persisted long after cessation of the
infusion. Meisenberg and Simmons18 reported that
AVP in cerebrospinal fluid is easily destroyed by
aminopeptidases and that its half-life in cerebrospinal
fluid is only a few minutes. Two possibilities may
explain the long-lasting hypotensive effect of AVP: 1)
The activity of aminopeptidases may be attenuated in
SHRSP. 2) Some metabolite of AVP may act centrally
to cause hypotension. Some of the central effects of
AVP, including those on behavior and memory, are
very long lasting.25 A protracted inhibitory effect of
lysine vasopressin on the centrally mediated pressor
response has also been reported.21 The results of the
present study are consistent with these earlier results,
although we have no evidence to support either of the
possible explanations.
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